| 77.84 0.86 (1.12%) | 05-22 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 94.66 | 1-year : | 100.24 |
| Resists | First : | 81.04 | Second : | 85.83 |
| Pivot price | 77.94  |
|||
| Supports | First : | 73.3 | Second : | 60.99 |
| MAs | MA(5) : | 77.21 |
MA(20) : | 79.41 |
| MA(100) : | 88.55 |
MA(250) : | 103.95 |
|
| MACD | MACD : | -1.7 |
Signal : | -1.9 |
| %K %D | K(14,3) : | 36.3 |
D(3) : | 33.3 |
| RSI | RSI(14): 45.9 |
|||
| 52-week | High : | 134.63 | Low : | 73.3 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ MRK ] has closed above bottom band by 49.0%. Bollinger Bands are 5.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 78.45 - 78.76 | 78.76 - 79.03 |
| Low: | 75.82 - 76.2 | 76.2 - 76.53 |
| Close: | 77.18 - 77.8 | 77.8 - 78.34 |
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Fri, 23 May 2025
Merck Showcases Innovation in Advanced Cancers and Rare Tumors at ASCO 2025 - BioSpace
Thu, 22 May 2025
Merck & Co. Stock: Inventory Doesn’t Lie (NYSE:MRK) - Seeking Alpha
Thu, 22 May 2025
AstraZeneca, Merck duke it out at the top of oncologists’ pharma perception ranking - Fierce Pharma
Thu, 22 May 2025
Merck to Participate in the Bernstein 41st Annual Strategic Decisions Conference - BioSpace
Thu, 22 May 2025
German Merck targets Phase III development of enpatoran - The Pharma Letter
Thu, 22 May 2025
Merck KGaA’s lupus drug to advance to Phase III despite mixed data - Clinical Trials Arena
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 2,510 (M) |
| Shares Float | 2,510 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 81.6 (%) |
| Shares Short | 37,140 (K) |
| Shares Short P.Month | 37,940 (K) |
| EPS | 6.88 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 19.2 |
| Profit Margin | 27.2 % |
| Operating Margin | 40 % |
| Return on Assets (ttm) | 13.8 % |
| Return on Equity (ttm) | 39.2 % |
| Qtrly Rev. Growth | -1.7 % |
| Gross Profit (p.s.) | 19.62 |
| Sales Per Share | 25.46 |
| EBITDA (p.s.) | 11.47 |
| Qtrly Earnings Growth | 7.5 % |
| Operating Cash Flow | 20,880 (M) |
| Levered Free Cash Flow | 17,120 (M) |
| PE Ratio | 11.31 |
| PEG Ratio | 0 |
| Price to Book value | 4.05 |
| Price to Sales | 3.05 |
| Price to Cash Flow | 9.35 |
| Dividend | 0.81 |
| Forward Dividend | 0 |
| Dividend Yield | 1% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|